Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

Sands Bruce E. and Peyrin-Biroulet Laurent and Loftus Edward V. and Danese Silvio and Colombel Jean-Frederic and Törüner Murat and Jonaitis Laimas and Abhyankar Brihad and Rogers Raquel and Chen Jingjing and Lirio Richard A. and Bornstein Jeffrey D. and VARSITY Study Group and Altorjay István and Molnár Tamás: Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
NEW ENGLAND JOURNAL OF MEDICINE, 381 (13). pp. 1215-1226. ISSN 0028-4793 (2019)

[thumbnail of 30999815_Sandsetal.VedolizumabvsadalimumabformoderatetosevereUC.pdf]
Preview
Text
30999815_Sandsetal.VedolizumabvsadalimumabformoderatetosevereUC.pdf - Published Version

Download (383kB) | Preview
[thumbnail of 30999815_melléklet.pdf]
Preview
Text
30999815_melléklet.pdf - Published Version

Download (2MB) | Preview
Item Type: Journal Article
Journal or Publication Title: NEW ENGLAND JOURNAL OF MEDICINE
Date: 2019
Volume: 381
Number: 13
Page Range: pp. 1215-1226
ISSN: 0028-4793
Faculty/Unit: Faculty of Medicine
Institution: Szegedi Tudományegyetem
Language: English
MTMT rekordazonosító: 30999815
DOI azonosító: https://doi.org/10.1056/NEJMoa1905725
Date Deposited: 2020. Aug. 29. 13:43
Last Modified: 2022. Oct. 27. 11:33
URI: http://publicatio.bibl.u-szeged.hu/id/eprint/19396
Web of Science® Times Cited: 443 View citing articles in Web of Science®

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year